AirSculpt Technologies just jumped 16.9% to about US$3.22, even though this stock has spent the past three months grinding lower. The spark was not a clean return to profits. It was a margin story in a turnaround quarter.

Q2 revenue landed at US$42.9 million, while adjusted earnings before interest, tax, depreciation and amortization came in at US$4.9 million with gross margin around 61%. For a business still posting losses, that level of gross profitability is what the market latched onto. The rest of the earnings detail tells a more complicated picture that you will want to unpack.

Love AirSculpt Technologies’ 61% gross margin but concerned about ongoing losses and the turnaround risk? Take a look at our hand picked list of resilient balance sheet stocks in the list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$42.9 million vs. US$44.0 million (declined about 2.5%)
• Net Loss, Q2 2026 vs. Q2 2025: US$1.112 million loss vs. US$0.591 million loss (loss widened)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.0157 loss per share vs. US$0.0099 loss per share (loss per share increased)
• Gross Margin, Q2 2026: Approximately 61% gross margin, supported by cost of services of about US$16.6 million on revenue of US$42.9 million

Prefer clean visuals instead of scrolling through dense earnings tables and footnotes? See AirSculpt Technologies’ full financial picture with a focus on its valuation in our company report for AirSculpt Technologies.

AirSculpt Turnaround Story Hinges On Margin And Mix

Bulls argue AirSculpt Technologies is in a margin-led turnaround where a richer service mix and improved marketing are turning a niche procedure into a broader aesthetics platform. Q2 results give some support to that view. Gross margin reached about 61% while case volumes grew and same-center revenue held roughly flat. That indicates the core procedure engine is stable even as average selling price eased.

The expansion beyond fat removal is starting to show up in operations rather than only in presentations. AirSculpt performed more than 200 skin excisions in Q2 and placed greater emphasis on upper blepharoplasty and mastopexy. Management is also focusing on GLP-1-related demand with new offerings and a planned AlloClae partnership. The trade-off is clear: customer acquisition cost rose to about US$3,500 per case as the company reinvests in the brand. Bulls see early proof of concept on mix and margins, but not yet on marketing efficiency.

Compare that 61% gross margin and expanding procedure mix with what the market is pricing in. See whether analysts view this AirSculpt Technologies turnaround as sustainable with the consensus price target analysis for AirSculpt Technologies.

AirSculpt Bears Still See Marketing And Mix Risk

The bearish view on AirSculpt Technologies centers on flatlining demand, slow payback from new procedures and rising customer acquisition cost eating into any gross margin strength. Q2 does not fully disprove that worry. Revenue declined 2.5% while same center sales were roughly flat and case volumes only inched higher. That is not the kind of uplift bears said would be needed to justify heavier spend on GLP 1 focused services.

Marketing intensity is exactly where skeptics pointed. Customer acquisition cost moved to about US$3,500 per case from roughly US$2,900, and adjusted EBITDA margin slipped to about 11.5% even with a 61% gross margin. New skin procedures are appearing in the mix but from a small base, so they have not yet delivered the operating leverage that might ease concerns about fixed clinic costs. In this quarter, the core bear narrative about pressured efficiency and slow monetization still looks intact.

After rising customer acquisition costs, widening losses and shareholder dilution, is this just the start of AirSculpt Technologies’ risk story? Review the risk analysis for AirSculpt Technologies which shows 3 important warning signs

Take Control Of Your Next Move

If the margin story at AirSculpt Technologies has your attention but the ongoing losses and marketing spend keep you cautious, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. Once you are invested, keep your decisions grounded in data by using the Portfolio Command Center to cut through noise and focus on the most important changes to your holdings. For a broader view beyond your own research, tap into the Community to see how other investors are thinking about similar risks and opportunities. This way you can spot potential catalysts or warning signs early and stay a step ahead of the market.

Seeking Alternatives Beyond AirSculpt?

Fresh stock ideas can move fast, and the best setups often fly before most investors notice. Scan these curated lists while it matters and get in early.

• Spot companies building tomorrow’s energy backbone and track potential breakout momentum using a curated basket of 36 power grid technology and infrastructure stocks before the crowd starts chasing them.
• Hunt for quieter compounding potential in a focused collection of 85 resilient stocks with low risk scores that aim to keep portfolios steadier when sentiment suddenly drops.
• Ride structural shifts in automation by reviewing hand picked 39 robotics and automation stocks that could benefit as demand for smarter factories and logistics gains traction.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.